For the quarter ending 2026-03-31, GRTX has $6,164K in assets. $1,141K in debts. $5,500K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 5,500 | 6,375 | 4,473 | 5,230 |
| Subscription receivable | - | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 563 | 720 | 428 | 717 |
| Total current assets | 6,063 | 7,095 | 4,901 | 5,947 |
| Other assets | 101 | 101 | 101 | 101 |
| Total assets | 6,164 | 7,196 | 5,002 | 6,048 |
| Accounts payable | 699 | 265 | 434 | 202 |
| Accrued expenses | 442 | 380 | 164 | 145 |
| Total current liabilities | - | 645 | 598 | 347 |
| Royalty purchase liability | - | 0 | 151,049 | 151,049 |
| Warrant liability | - | 0 | 0 | 0 |
| Liabilities | 1,141 | 645 | 151,647 | 151,396 |
| Series b redeemable convertible preferred stock, 0.001 par value 10,000,000 shares authorized 119,318 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 4,295 | 2,577 | 2,577 | 2,597 |
| Common stock, 0.001 par value 200,000,000 shares authorized 75,462,390 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 75 | 75 | 75 | 75 |
| Additional paid-in capital | 309,573 | 311,213 | 311,121 | 311,010 |
| Accumulated deficit | -308,920 | -307,314 | -460,418 | -459,030 |
| Total stockholders' deficit | 728 | 3,974 | -149,222 | -147,945 |
| Total liabilities, redeemable convertible preferred stock and stockholders equity | 6,164 | 7,196 | 5,002 | 6,048 |
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)